Clinical Trials Browser

Phase 1/2 × Lymphoma, Non-Hodgkin × TIC10 compound × Clear all

NCT02420795 2022-04-04

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

16 enrolled 14 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell